A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis - 09/08/11
Kansas City, Missouri; Lynchburg, Virginia; Minneapolis, Minnesota; Louisville, Kentucky; Washington, District of Columbia; Hershey, Pennsylvania; New York, New York; and Deerfield, Illinois
Abstract |
Objective |
Tolerability and safety of 0.1% tacrolimus ointment in treating nickel-induced allergic contact dermatitis (ACD) were evaluated.
Methods |
Patients allergic to nickel applied nickel patches to each upper inner aspect of the arm for 4 to 8 hours daily. Tacrolimus was applied to patch site on one arm and vehicle to patch site on the other, twice daily. Physician’s Global Assessment, signs and symptoms of ACD, pruritus scores, and adverse events were evaluated.
Results |
After 8 weeks, dermatitis in 45% of patients was clear or almost clear (Physician’s Global Assessment) with tacrolimus; and 1% with vehicle (P < .001). Significant results were achieved as early as day 8. Tacrolimus was superior in ACD signs and symptoms improvement and pruritus reduction (P < .001). Adverse events were similar between treatments.
Limitations |
This model, involving one agent, may not be generalizable for other agents.
Conclusions |
Tacrolimus ointment 0.1% is well tolerated and significantly more effective than vehicle in treating chronically exposed, nickel-induced ACD.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ACD, AE, PGA
Plan
Supported by Astellas Pharma US, Inc. Disclosure: All authors, except Mrs Willets and Mr Rutledge, were investigators in this trial sponsored by Astellas Pharma US, Inc. Dr Belsito is a consultant, a grant/research support recipient, and on the speaker’s bureau for Astellas Pharma US, Inc. Dr Warshaw has performed clinical trials for several pharmaceutical companies including Astellas Pharma US, Inc, Dermik, Novartis, Paddock, and Teva. Mrs Willetts and Mr Rutledge are employees of Astellas Pharma US, Inc. |
Vol 55 - N° 1
P. 40-46 - juillet 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?